Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups.
Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups.
复制标题
DOI：
10.3389/fonc.2022.943154
复制
发表时间：
2022
影响因子：
4.7
通讯作者：
Bujkiewicz, Sylwia
中科院分区：
文献类型：
--
作者：
Umemneku-Chikere, Chinyereugo M. M.;Ayodele, Olubukola;Soares, Marta;Khan, Sam;Abrams, Keith;Owen, Rhiannon;Bujkiewicz, Sylwia
关键词：
乳腺癌是全球癌症相关死亡的第五大原因。人类表皮受体 2 (HER2) 阳性晚期乳腺癌 (ABC) 靶向治疗的随机对照试验 (RCT) 为监管和报销机构评估癌症疗法在临床实践中的使用提供了证据基础。然而，这些患者中的一部分具有额外的生物标志物，例如，激素受体状态呈阳性，可能更适合治疗并提高总生存期 (OS)。本综述旨在利用 HER2 阳性 ABC 患者靶向治疗的 RCT 证据，探索激素受体状态的治疗效果证据报告。遵循系统评价和荟萃分析的首选报告项目 (PRISMA) 指南来确定已发表的随机对照试验。使用网络荟萃分析合成提取的数据，以获得 HER2 阳性靶向治疗的相对效果。我们发现在根据激素受体状态报告治疗有效性方面存在差距，因为在 42 项已确定的随机对照试验中，只有 15 项报告了激素受体亚组分析；其中大多数报告了无进展生存期，但没有报告 OS 或总体缓解率。总之，我们建议 ABC 未来的试验应报告癌症治疗对激素受体亚组所有结局的影响。
Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)–positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.
登录
查看更多内容
影响因子：
3.9
作者：
Chen F;Chen N;Lv Z;Li L;Cui J
通讯作者：
Cui J
影响因子：
9.3
作者：
Cope, Shannon;Zhang, Jie;Schmid, Peter
通讯作者：
Schmid, Peter
影响因子：
3.8
作者：
Cameron, David;Casey, Michelle;Geyer, Charles E.
通讯作者：
Geyer, Charles E.
影响因子：
45.3
作者：
Di Leo, Angelo;Gomez, Henry L.;Press, Michael F.
通讯作者：
Press, Michael F.
DOI：
10.1093/noajnl/vdaa136
发表时间：
2020-01
期刊：
Neuro-oncology advances
影响因子：
--
作者：
Erickson AW;Ghodrati F;Habbous S;Jerzak KJ;Sahgal A;Ahluwalia MS;Das S
通讯作者：
Das S